Insmed (STU:IM8N) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IM8N Insmed Inc STU:IM8N
71 GF Score
Price €85.69
GF Value €161.73
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed FFO per Share?

FFO per Share only applies to REITs.

STU:IM8N
71GF Score
Insmed Inc STU:IM8N
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insmed (STU:IM8N) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €85.69 is trading 47% below its estimated GF Value™ of €161.73. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for STU:IM8N:

  • FFO per Share:
  • GF Value™: €161.73 vs. price of €85.69 (47% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the STU:IM8N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
71GF Score

Get the complete analysis for STU:IM8N

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€85.69
Price
€161.73
GF Value